ArticleFrontiers in medicine2025
Protocol for a systematic review of sarcopenia in older adults with type 2 diabetes mellitus and its association with increased risk of mortality.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial-Bioenergetic-Immune Axis in Type 2 Diabetes Mellitus-Associated Sarcopenia: A Review from Pathogenesis to Targeted Reconstruction.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia and type 2 diabetes mellitus (T2DM) are prevalent health conditions that significantly impact mortality risk, particularly among older adults. While both conditions have been individually associated with increased mortality, limited evidence exists regarding their combined effect, and no prior systematic review has synthesized this association specifically among older adults with T2DM. This study aims to examine the association between sarcopenia and all-cause mortality in older adults with T2DM. It seeks to evaluate whether this relationship varies by population characteristics, sarcopenia definitions, and follow-up duration. Methods: We will conduct a comprehensive literature search using databases such as PubMed, Scopus, CINAHL, and Embase to identify studies exploring the relationship between sarcopenia and all-cause mortality in older adults with T2DM from January 1, 2014, to September 1, 2024. Two authors will independently screen all eligible clinical studies. Statistical analyses will be conducted using JBI SUMARI software. Results: Preliminary findings will indicate the overall prevalence and mortality rate among older adults with sarcopenia and T2DM. By consolidating findings from diverse studies, this meta-analysis will provide clearer insights into how sarcopenia and T2DM interact to affect mortality risk. Conclusion: Understanding the relationship between sarcopenia and T2DM is crucial leading to developing effective interventions to reduce mortality risk and improve the quality of life in older adults. Addressing this important research gap will contribute to better healthcare practices and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.